ClinicalTrials.gg
RecruitingNCT06099522Updated Mar 8, 2024

Internet-CBT for Gambling Disorder - a Randomized Controlled Trial

An interventional study of Internet-based cognitive behavioral therapy (iCBT) in Gambling Disorder, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is a randomized controlled trial (Total N=150; each condition n=75) of internet-based cognitive behavioral therapy (iCBT), with measures at pre, weekly during treatment, post, three and at six month follow-up. Participants will be assigned to either standard iCBT and "Spelpaus" (treatment condition), or "Spelpaus" only (control condition).

Read the detailed description

Recruitment will be done through online advertisement via social media and gambling-related websites. Participants will self-referred to the study via a study dedicated website (www.spelstudien.se). Login to a treatment platform will be verified using double authentication (detailed description of the online platform is provided in the application to the Swedish Ethical Review Authority). Written information about the study will be provided on the web page. Consent will be done online, with the possibility for participants to download study information and consent. Consenting participants will start a screening procedure. After screening, participants will be contacted for a telephone assessment with a clinical psychologist. During this interview, participants will be assessed for GD with a diagnostic interview, as well as the inclusion criteria for utilization of "Spelpaus". If meeting criteria for the study, participants will be referred to the baseline/pre-measures - which will start with an additional informed consent for the treatment phase and the iCBT. Inclusion will be done after the completion of the informed consent and baseline/pre-measures. After that, participant will be randomized to iCBT and "Spelpaus" (treatment condition), or "Spelpaus" only (control condition). Randomization will be conducted by a third party using a true random service, https://random.org. Participants assigned to the control condition in the randomized controlled trial will receive a voucher of total 1000 Swedish Krona's when completing the post and follow up measures. Participants assigned to the control condition in the randomized controlled trial will receive a voucher of total 1000 Swedish Krona's when completing the post and follow up measures.

02

Conditions studied

  • Gambling Disorder

Browse trials for

03

In context

Gambling

158 studies on the registry are indexed under Gambling; 42 are open to participants now.

This study's planned enrollment of 150 is above the median of 66 across 128 interventional studies indexed under Gambling.

Browse Gambling studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,148 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Screen positive for GD, as measured with the Gambling Disorder Identification Test (total score ≥20 GDIT).
  • Fulfilling GD, assessed according to the Structured Clinical Interview for Gambling Disorder (SCI-GD).
  • Utilization of "Spelpaus", 3 months from treatment start.
  • ≥18 years of age.
  • Able to provide digital .

Exclusion criteria

Exclusion Criteria:

  • Other ongoing psychological treatment for GD.
  • Severe depression, screened according to the Montgomery Åsberg Depression Rating Scale (total score >34 MADRS-S).
  • Suicidality, screening of ≥4 points on item 9 of the MADRS-S
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Internet-based cognitive behavioral therapy (iCBT)

    An 8-module internet-delivered cognitive behavioral therapy program. Participants receiving treatment will simultaneously use "Spelpaus" - a self-exclusion gambling service.

    Behavioral: Internet-based cognitive behavioral therapy (iCBT)

  • No intervention
    "Spelpaus" (gambling self-exclusion)

    "Spelpaus" only - a self-exclusion gambling service.

Interventions

  • BehavioralInternet-based cognitive behavioral therapy (iCBT)

    The treatment is a newly developed iCBT 8 module program, with interventions targeting gambling-related loss of control, through 4 clinical processes: Gambling triggers, Gambling-related anticipation, the Gambling zone and Chasing behaviors. The treatment will be delivered with therapist support.

06

What researchers measure

Primary outcomes

  1. The Gambling Symptom Assessment Scale

    Primary outcome will be gambling symptoms, measured with the the Gambling Symptom Assessment Scale. Minimum score is 0 and maximum score is 48, with higher scores indicated higher frequency of gambling symptoms.

    Time frame: 6 month after treatment cessation

Secondary outcomes

  1. The TimeLine Followback for gambling

    Gambling behavior (days per week gambled) will be measured with a self-report item adapted from the TimeLine Followback for gambling.

    Time frame: 6 month after treatment cessation

  2. The Generalized Anxiety Disorder 7-itemscale

    Anxiety symptoms will be measured by the Generalized Anxiety Disorder 7-itemscale.

    Time frame: 6 month after treatment cessation

  3. The Patient Health Questionnaire

    Depressive symptoms will be measured with the The Patient Health Questionnaire.

    Time frame: 6 month after treatment cessation

  4. The Alcohol Use Disorders Identification Test

    Alcohol problems will be measured with the Alcohol Use Disorders Identification Test.

    Time frame: 6 month after treatment cessation

  5. The Drug Use Disorders Identification Test

    Drug problems will be measured with the Drug Use Disorders Identification Test.

    Time frame: 6 month after treatment cessation

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06099522
Collaborators
Deakin University
Responsible party
Olof Molander (Principal Investigator, Karolinska Institutet) — Principal investigator
First posted
Oct 25, 2023
Start date
Jan 15, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Mar 8, 2024

Study contacts

Olof Molander, PhD
Contact
olof.molander@ki.se
0700011241

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion